SAM
PGNX

Symphony Asset Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Symphony Asset Management’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-85,000
Closed -$366K – 453
2014
Q2 		$366K Hold
85,000
– – 0.04% 365
2014
Q1 		$348K Buy
+85,000
New +$435K 0.03% 366

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Symphony Asset Management's PGNX Position: Q3 2016 in Review

Symphony Asset Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q3 2016, closing a stake of 14,890 shares — an estimated $63K sold.

Symphony Asset Management first reported a position in PGNX in Q2 2014 and held it in 6 quarters. The position peaked at $295K in Q3 2015. 115 funds tracked by Wall St. Rank hold PGNX as of Q3 2016.

  • Symphony Asset Management reported no remaining Progenics Pharmaceuticals Inc position as of Q3 2016 after selling out during the quarter.
  • Symphony Asset Management sold 14,890 Progenics Pharmaceuticals Inc shares in Q3 2016, an estimated $63K.
  • Symphony Asset Management first reported a position in Progenics Pharmaceuticals Inc in Q2 2014 and held it in 6 quarters.
  • Symphony Asset Management's Progenics Pharmaceuticals Inc position peaked at $295K in Q3 2015.
  • 115 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q3 2016.

Based on Symphony Asset Management's 13F filing for Q3 2016, filed 14 Nov 2016.